2023 World Conference on Lung Cancer (Posters)-EP12.01. Autopsy and Next Generation Sequencing Report of First-Line Treatment with Osimertinib for EGFR-Mutated Squamous Cell Carcinoma of the Lung

EP12.01. Autopsy and Next Generation Sequencing Report of First-Line Treatment with Osimertinib for EGFR-Mutated Squamous Cell Carcinoma of the Lung - PDF(Abstract)

Back to course

Pdf Summary

This session at WCLC 2023 presents a case report on the use of osimertinib as a first-line treatment for EGFR-mutated squamous cell carcinoma (SCC) of the lung. The study aims to understand the efficacy of osimertinib in SCC, a less common form of lung cancer. The patient in the case report was an 83-year-old male diagnosed with SCC of the lung positive for EGFR exon19 deletion. He was treated with osimertinib but showed no response and experienced disease progression. The patient died three weeks later.<br /><br />An autopsy and next-generation sequencing analysis were performed to investigate the ineffectiveness of osimertinib. The autopsy confirmed the lung SCC diagnosis, and the next-generation sequencing revealed multiple genetic abnormalities, including TP53 mutation and amplification of CDK6 and KRAS. These genetic abnormalities have previously been associated with resistance to osimertinib. <br /><br />The report concludes that next-generation sequencing can provide insights into why osimertinib is ineffective in EGFR-mutated SCC. Therefore, the therapeutic strategy for these patients should involve analyzing coexisting genetic abnormalities. If no additional genes associated with resistance to tyrosine kinase inhibitors are detected, therapy with EGFR tyrosine kinase inhibitor may be recommended.<br /><br />This study highlights the importance of personalized medicine and the need for genetic analysis to guide treatment decisions. Understanding the genetic profile of tumors can help identify potential resistance mechanisms and tailor treatments accordingly. Therefore, next-generation sequencing can play a crucial role in improving the efficacy of targeted therapies for EGFR-mutated SCC.

Asset Subtitle

Tadashi Nishimura

Meta Tag

Speaker Tadashi Nishimura

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

WCLC 2023

osimertinib

first-line treatment

EGFR-mutated

squamous cell carcinoma

lung cancer

efficacy

genetic abnormalities

next-generation sequencing

personalized medicine